To date, two classes of PI3K inhibitors have been evaluated for the treatment of GC: pan-PI3K inhibitors, which target all PI3K family members (BKM120, PX-886, and XL147), and isoform-specific PI3K inhibitors, which specifically target the p110 catalytic subunit of PI3K (BYL719, GDC0032, and INK1117) [113]. Here, PIK3CA is linked to gastric cancer.